bambuterol

Small moleculeexperimental

Clinical trial activity

3 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
2

Earliest trial started Mar 1, 2012 (NCT01566565)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1
Mol. weight
367.45 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate)
  • (±)-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate)
  • (±)-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate)
  • bambudil
  • bambuterol
  • bambuterol
  • bambuterol
  • bambuterol
  • bambuterol
  • bambuterol
  • bambuterol
  • bambuterol
  • (+/-)-bambuterol
  • bambutérol
  • bambutérol
  • bambuterol hcl
  • bambuterol hydrochloride
  • bambuterol hydrochloride
  • bambuterol hydrochloride
  • bambuterol hydrochloride
  • bambuterolum
  • bambuterolum
  • terbutaline bisdimethylcarbamate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01796730Phase 4Feb 1, 2013Guangzhou Medical University, Southern Medical University
NCT02002754Phase 4Jun 1, 2012Guangzhou Medical University
NCT01566565Phase 1Mar 1, 2012Duke University, Norwegian Military, Osaka University
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Guangzhou Medical UniversityAcademic/Hospital2212012
Duke UniversityAcademic/Hospital1012012
Norwegian MilitaryGovernment1112012
Osaka UniversityAcademic/Hospital1012012
Southern Medical UniversityAcademic/Hospital1012013
5 organizations
Page 1 / 1